New combo therapy may beat chemo for rare kidney cancer

NCT ID NCT06120374

Recruiting now Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a combination of radiation and immunotherapy works better than standard chemotherapy after surgery for a rare type of kidney cancer called upper tract urothelial carcinoma. About 178 patients with high-risk features will be followed to see which treatment helps prevent the cancer from coming back. The goal is to find a more effective way to keep patients cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiotherapy (SBRT) and immunotherapy
What this could lead to: If successful, this could show that combining radiation and immunotherapy is a better option than standard chemotherapy for preventing cancer recurrence after surgery.
What could go wrong: This is an observational study, not a randomized trial, so results may be less reliable. The combination therapy may also cause more side effects, and it is unclear which patients benefit most.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CARCINOMA

Contacts and locations

Locations

Departmeng of Urology, Peking University First Hospital
RECRUITING

Beijing, China
Department of Medical Oncology, Peking University First Hospital
RECRUITING

Beijing, China
Department of Radiotherapy Oncology, Peking University First Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.